CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.

CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics is a biopharmaceutical company with operations in China and the U.S. focused on developing innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

CARsgen Therapeutics

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Media contact: pr@carsgen.com

JIC Genesis Fountain Healthcare Ventures

Kaitai Capital

Summer Capital

Lilly Asia Ventures

Loyal Valley Capital

Shiyu Capital

South China Venture Capital

Photon Fund

Jolly Innovation Ventures

KTB Ventures

"In the past six months, we have made significant progresses in technological innovation, product development, and business operations. Zevor-cel was successfully launched in China and has been included in nearly 20 provincial and municipal healthcare plans. The pivotal Phase II trial of satri-cel in China has completed patient enrollment. We are also actively exploring the potential of satri-cel in adjuvant therapy, aiming for greater clinical benefit for patients. Additionally, we are rapidly advancing CT071, which is manufactured with our CARcelerate® platform, while continuing to develop multiple allogeneic CAR T-cell products based on the THANK-uCAR® platform." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gmubHD2Y

#cartcelltherapy #biotech #hematology #oncology

"We are very pleased to announce the successful completion of patient enrollment in the pivotal Phase II clinical trial of satri-cel in China. This significant milestone marks another solid step forward in our development of CAR T-cell therapies for solid tumors. We extend our gratitude to all the investigators, the patients and their families for their trust and support. We look forward to the submission of New Drug Application and the approval in China, to benefit patients with gastric cancer. As one of the leading companies in the field of CAR T-cell therapies, we remain committed to addressing the major challenges faced by existing CAR T-cell therapies and will develop more innovative CAR-T products for cancer patients." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gZjZdQZa

The updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). 

https://lnkd.in/gEKkNrwb

#cartcelltherapy #eha2024 #multiplemyeloma #bcma #gprc5d #carcelerate

The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)"

https://lnkd.in/g3R_eYun

#eha #eha2024 #rrmm #cartcelltherapy #gprc5d

The final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting.

https://lnkd.in/gnsCAqeq

The FDA has granted IND clearance for CT071, an autologous CAR T-cell therapy candidate targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (MM) or relapsed/refractory primary plasma cell leukemia (PCL).

CT071 is manufactured with CARsgen's proprietary CARcelerate™ platform, which shortens the manufacturing time to less than 2 days and therefore yields younger, healthier, and possibly more potent CAR T cells compared to conventional manufacturing. 

https://lnkd.in/gjx2kUiH

#cartcelltherapy #GPRC5D #CARcelerate

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory					341.50K -
average payables
average receivables					11.32M -
book value per share	-1.29 -	-2.95 128.79%	7.75 362.21%	4.48 42.12%	3.24K 72,160.36%
capex per share	-0.18 -	-0.03 81.89%	-0.46 1,296.99%	-0.25 45.53%	-17.17 6,733.18%
capex to depreciation	-5.29 -	-0.47 91.16%	-3.40 628.45%	-1.70 50.04%	-0.11 93.57%
capex to operating cash flow	0.58 -	0.06 89.02%	0.35 448.74%	0.22 38.12%	0.02 90.26%
capex to revenue			-6.91 -
cash per share	0.17 -	1.84 981.07%	7.77 322.84%	4.11 47.11%	3.33K 80,797.64%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets	0.26 -	0.08 69.11%	0.10 20.60%	0.04 55.17%	0.04 12.67%
debt to equity	-0.12 -	-0.06 48.03%	0.11 288.59%	0.05 57.19%	0.05 2.06%
dividend yield
earnings yield	-0.02 -	-0.13 528.44%	-0.55 333.80%	-0.12 77.85%	-0.24 95.19%
enterprise value	15.17B -	13.36B 11.92%	8.33B 37.66%	5.22B 37.31%	-1.76B 133.73%
enterprise value over ebitda	-73.49 -	-46.69 36.47%	-16.08 65.55%	-6.58 59.11%	2.46K 37,534.68%
ev to operating cash flow	-84.74 -	-45.27 46.58%	-16.26 64.09%	-8.12 50.06%	3.87 147.68%
ev to sales			322.67 -
free cash flow per share	-0.50 -	-0.55 11.12%	-1.79 222.77%	-1.42 20.65%	-835.22 58,841.89%
free cash flow yield	-0.02 -	-0.02 17.94%	-0.08 262.56%	-0.11 33.31%	-146.78 138,290.58%
graham net net	-1.70 -	-3.33 96.17%	6.46 294.15%	3.59 44.46%	2.54K 70,671.30%
graham number	3.95 -	14.53 268.07%	46.24 218.22%	12.77 72.37%	313.08 2,350.95%
income quality	0.68 -	0.28 58.92%	0.11 61.01%	0.72 567.31%	0.61 15.66%
intangibles to total assets	0.11 -	0.02 77.68%	0.01 68.39%	0.01 0.51%	0.01 12.23%
interest coverage	-256.37 -	-24.26 90.54%	-53.91 122.22%	-56.78 5.32%
interest debt per share	0.15 -	0.20 33.47%	0.90 349.92%	0.24 72.87%	153.24 62,531.02%
inventory turnover
invested capital	-0.12 -	-0.06 48.03%	0.11 288.59%	0.05 57.19%	0.05 2.06%
market cap	15.18B -	14.30B 5.78%	8.68B 39.30%	7.37B 15.11%	3.16M 99.96%
net current asset value	-943.41M -	-1.87B 98.66%	2.56B 236.69%	2.01B 21.50%	1.42B 29.51%
net debt to ebitda	0.06 -	3.29 5,496.13%	0.68 79.29%	2.71 296.79%	2.47K 91,034.17%
net income per share	-0.54 -	-3.18 492.13%	-12.26 286.19%	-1.62 86.81%	-1.34 16.87%
operating cash flow per share	-0.32 -	-0.52 64.88%	-1.32 154.58%	-1.17 11.98%	-818.04 70,074.33%
payables turnover
receivables turnover
research and ddevelopement to revenue			19.44 -
return on tangible assets	-1.05 -	-1.47 40.53%	-1.36 7.40%	-0.33 76.14%	-0.00 99.90%
revenue per share			0.07 -
roe	0.42 -	1.07 158.81%	-1.58 247.28%	-0.36 77.21%	-0.00 99.88%
roic	0.41 -	0.36 13.07%	-0.17 147.85%	-0.33 91.59%	-0.00 99.87%
sales general and administrative to revenue			2.55 -
shareholders equity per share	-1.29 -	-2.95 128.79%	7.75 362.21%	4.48 42.12%	3.24K 72,160.36%
stock based compensation to revenue			0.52 -
tangible asset value	-768.07M -	-1.71B 122.19%	2.97B 274.02%	2.45B 17.43%	1.79B 27.14%
tangible book value per share	-1.35 -	-3.01 122.19%	7.68 355.22%	4.45 42.10%	3.21K 72,170.13%
working capital	-906.37M -	910.56M 200.46%	2.68B 194.51%	2.13B 20.59%	1.68B 21.26%

2171

COM:CARSGEN

CARsgen Therapeutics

Last Close

7.02

25/11 08:08

Market Cap

2.36B

Beta: -

Volume Today

8.53M

Avg: -

Preview